JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
Malik, Abhidha; Jeyaraj, Pamela Alice; Calton, Rajneesh; Uppal, Bharti; Negi, Preety; Shankar, Abhishek; Patil, Jaineet; Mahajan, Manmohan Kishan;
  PDF(new window)
 Abstract
Background: The early detection of anthracycline- induced cardiotoxicity is very important since it might be useful in prevention of cardiac decompensation. This study was designed with the intent of assessing the usefulness of cardiac troponin T (cTnT) and NT- Pro BNP estimation in early prediction of anthracycline induced cardiotoxicity. Materials and Methods: In this prospective study histologically proven breast cancer patients who were scheduled to receive anthracycline containing combination chemotherapy as a part of multimodality treatment were enrolled. Baseline cardiac evaluation was performed by echocardiography (ECHO) and biomarkers like cardiac troponin T (cTnT) and N terminal- pro brain natriuretic peptide (NT- Pro BNP). All patients underwent cTnT and NT- Pro BNP estimation within 24 hours of each cycle of chemotherapy and were followed up after 6 months of initiation of chemotherapy. Any changes in follow up ECHO were compared to ECHO at baseline and cTnT and NT- Pro BNP levels after each cycle of anthracycline-based chemotherapy. Results: Initial data were obtained for 33 patients. Mean change in left ventricular diastolic diameter (LVDD) within 6 months was (p value
 Keywords
Anthracycline;breast cancer;cardiotoxicity;
 Language
English
 Cited by
 References
1.
Adamcova M, Sterba M, Simunek T et al (2005). Troponin as a marker of myocardiac damage in drug induced cardiotoxicity. Expert opin Drug Saf, 4, 37-46.

2.
Appel JM, Nielsen D, Zerahn B et al (2007). Anthracyclineinduced chronic cardiotoxicity and heart failure. Acta Oncologica, 46, 576-80. crossref(new window)

3.
Billingham ME, Masek MA (1993). The pathology of anthracycline cardiotoxicity in children, adolescents and adults. In: Bricker JT, Green DM, D'Angio G (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York; 17-24.

4.
Broeyer FJF, Osanto S, Ritsema vaneck HJ et al (2008). Evaluation of biomarkers for cardiotoxicity of anthracycline based chemotherapy. J Cancer Res Clin Oncol, 134, 961-68. crossref(new window)

5.
Cardinale D, Sandri MT, Colombo A et al (2004). Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109, 2749-54. crossref(new window)

6.
Cardinale D, Sandri MT, Martinoni A et al (2002). Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol, 13, 710-15. crossref(new window)

7.
Chia S, Bryce C, Gelmon K. Early Breast Cancer Trialist’s Collaborative group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet, 365, 1687-1717. crossref(new window)

8.
Elliott P (2006). Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol, 33, 2-7. crossref(new window)

9.
Ewer MS, Martin FJ, Henderson IC et al (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol, 31, 161-81. crossref(new window)

10.
Frishman WH, Sung HM, Yee HC et al (1997). Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer, 21, 301-60. crossref(new window)

11.
Katus HA, Remppis A, Neumann FJ et al (1991). Diagnostic efficiency of troponin T measurement in acute myocardial infarction. Circulation, 83, 1360-67.

12.
Kilickap S, Barista I, Akgul E et al (2005). cTnT can be a useful marker for early detection of anthracycline toxicity. Ann Oncol, 16, 798-804. crossref(new window)

13.
Nistico C, Bria E, Cuppone F et al (2007). Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients. Anticancer Drugs, 18, 227-32. crossref(new window)

14.
Nysom K, Holm K, Lipsitz SR et al (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol, 16, 545-50. crossref(new window)

15.
Ryberg M, Nielsen D, Skovsgaard T et al (1998). Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol, 16, 3502-08. crossref(new window)

16.
Sandri MT, Salvatici M, Cardinale D et al (2005). N-terminal pro B- type natriuretic peptide after high dose chemotherapy; marker predictive of cardiac dysfunction? Clin Chem, 51, 1405-10. crossref(new window)

17.
Sawaya H, Sebag IA, Plana JC, et al (2012). Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circ Cardiovasc Imag, 5, 596-603. crossref(new window)

18.
Saxena S, Rekhi B, Bansal A, et al (2005). Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India- A cross-sectional study. World J Surg Oncol, 3, 67. crossref(new window)

19.
Steven ME and Michael SE (2009). Anthracycline cardiotoxicity: Why are we still interested? Oncol, 23, 3.

20.
Suter TM and Meier B (2002). Detection of anthracyclineinduced cardiotoxicity: is there light at the end of the tunnel? Ann Oncol, 13, 647-9. crossref(new window)

21.
Tsutamoto T, Wada A, Maeda K, et al (1999). Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimal symptomatic left ventricular dysfunction. E Heart J, 20, 1799-80. crossref(new window)

22.
Von Hoff DD, Layard MW, Basa P et al (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 91, 710-7 crossref(new window)

23.
Willial FA, Ruth MP, Grace MD et al (2006). Cancer Epidemiology. Biomarkers and Prevent, 15, 1899-905. crossref(new window)

24.
Yancik R, Wesley MN, Ries LA et al (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 285, 885-92. crossref(new window)

25.
Yau TK (2005). Cardiotoxicity after adjuvant anthracyclinebased chemotherapy and radiotherapy for breast cancer. J HK Coll Radiol, 8, 26-9.